[CAS NO. 2750001-23-9] AZD0095
PRODUCTS SPECIFICATIONS [2750001-23-9]
DESCRIPTION [2750001-23-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 500.60 |
| Molecular Formula | C27H32N8O2 |
| SMILES | CC1=C(O[C@H]2CN(C3=CC=C(C4=NN=C(CN5CCOCC5)C=C4)C=C3)CC2)C(C)=NC6=NC(C)=NN16 |
Summary
IC50 & Target
|
MCT4 1.3 nM (IC 50 ) |
In Vitro
AZD0095 (0-50 µM) inhibits cell proliferation in NCI-H358 cells (high expression of MCT4), with an IC
50
of 26 nM
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
AZD0095 (100 mg/kg, p.o. bid) together with
Cediranib
(3 mg/kg, p.o.) reduces tumor growth in a murine NCI-H358 xenograft
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Murine NCI-H358 xenograft [1] |
| Dosage: | 100 mg/kg together with Cediranib (3 mg/kg) |
| Administration: | Oral administration (p.o.) |
| Result: | Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
